⌘K

Home/Filings/4/0001104659-22-026182

4//SEC Filing

Kruse Bo 4

Accession 0001104659-22-026182

CIK 0001722964other

View on SEC.gov Company Profile

Filed

Feb 22, 7:00 PM ET

Accepted

Feb 23, 5:15 PM ET

Size

4.7 KB

Accession

0001104659-22-026182

Insider Transaction Report

Form 4

Period: 2022-02-22

Y-mAbs Therapeutics, Inc.YMAB

DirectorEVP, CFO, Secy & Treas.

Transactions

Sale
Common Stock
2022-02-22$7.85/sh−4,000$31,400→ 181,077 total

Footnotes (1)

[F1]Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2021.

Documents

1 file

4
tm225222-5_4seq1.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Y-mAbs Therapeutics, Inc.

CIK 0001722964

Entity typeother

Related Parties

1

filerCIK 0001752940

Filing Metadata

Form type: 4
Filed: Feb 22, 7:00 PM ET
Accepted: Feb 23, 5:15 PM ET
Size: 4.7 KB

View on SEC.gov